Objective
The present project will help to develop fosmidomycin, an inhibitor of the DOXP reductoisomerase, into an antimalarial drug. In parallel to the clinical evaluation of fosmidomycin in human volunteers, tests with derivatives of fosmidomycin with demonstrably improved pharmacological profiles in two different non-human primate models will be the pre-requisite for a straight forward clinical development of a second generation of DOXP reductoisomerase inhibitors as antimalarial drugs. Furthermore, biochemical, molecular biological and pharmacological studies will increase our knowledge about the relevance of the DOXP pathway for the survival of malaria parasites, and demonstrate its potential as a new target for chemotherapy. Finally, new DOXP reductoisomerase inhibitors with improved antimalarial activity will be developed.
Fields of science
Topic(s)
Data not availableCall for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
35392 GIESSEN
Germany